Review Note

*AnKing::#AK_Step1_v11::##FirstAid##::10_Hematology_Oncology::04_Pathology::25_Non-Hodgkin_Lymphoma::Follicular_Lymphoma *AnKing::#AK_Step1_v11::##FirstAid##::10_Hematology_Oncology::05_Pharm::23_Rituximab *AnKing::#AK_Step1_v11::#B&B::11_Hematology::03_WBC::04_Non-Hodgkin_Lymphoma *AnKing::#AK_Step1_v11::#OME::13_Hematology_Oncology::04_Proliferation::04_Lymphoma *AnKing::#AK_Step1_v11::#OME_banner::Clinical::05_Hematology_Oncology::06_Lymphoma *AnKing::#AK_Step1_v11::#Pathoma::06_WBC::06_Lymphoma *AnKing::#AK_Step1_v11::#Physeo::11_Pathology::10_HemeOnc_Pathology::16_Non-Hodgkin_Lymphoma *AnKing::#AK_Step1_v11::#Pixorize::01_Immunology::07_Leukemias_&_Lymphomas::09_Follicular_Lymphoma *AnKing::#AK_Step1_v11::#Pixorize::02_Biochem::22_Onc_Drugs::02_Rituximab *AnKing::#AK_Step1_v11::#SketchyPath::10_Myeloid_&_Lymphoid::02_Lymphoid_&_Plasma_Cell_Disorders::03_Non-Hodgkin_Lymphoma *AnKing::#AK_Step1_v11::^Other::^HighYield::1-HighYield *AnKing::#AK_Step1_v11::^Systems::HemeOnc::WBC *AnKing::Mazo_Originales_AnKing::USMLE_Step_1_|_Ciencias_Básicas::Zanki_Step_Decks::Zanki_Hematology_&_Oncology::Pathoma_WBC